Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn. Yu Seok YS; Lee. Kang Choon KC
Key Findings
- Targeted PEGylation at Lys21 yields a single, high‑purity peptide product (~95% yield).
- Lys21‑PEG‑GRF‑1‑29 is dramatically more resistant to degradation: 7‑ to 25‑fold longer half‑life in plasma, liver, and kidney homogenates.
- In rats, the PEGylated peptide stays in the blood longer, distributes less to liver/kidney, and triggers a stronger initial growth hormone release despite lower in‑vitro activity.
Practical Outcomes
- For biohackers, the take‑away is that a PEG‑linked version of GRF‑1‑29 can act as a longer‑lasting growth‑hormone‑releasing peptide, potentially reducing injection frequency. While the exact chemistry isn’t DIY‑friendly, the data support using commercially available Lys‑21‑PEG‑GRF analogs (e.g., CJC‑1295) for more sustained GH effects.
Summary
Scientists figured out a way to attach a PEG molecule specifically to the 21st amino acid of the growth hormone‑releasing factor peptide (GRF‑1‑29). This makes the peptide much more stable in the body—lasting up to 25 times longer in some tissues—so it can boost growth hormone release for a longer period, even though its activity in a test tube looks a bit lower.
Abstract
PEGylation has been viewed as an effective means of overcoming the therapeutic restriction of growth hormone-releasing factor (1-29) (GRF(1-29)) due to its short biological lifetime caused by severe proteolysis and rapid glomerular filtration. Of three isomers according to the PEGylation sites (Tyr1, Lys12, or Lys21), PEGylated GRF(1-29) at Lys21-amine (Lys21-PEG-GRF(1-29)) was shown to have the highest bioactivity. In this report, we propose a unique two-step site-specific PEGylation method capable of producing only Lys21-PEG-GRF(1-29) with a single composition in high yield using a GRF(1-29) derivative protected at Tyr1 and Lys12 and remained available at Lys21 (FMOC1,12-GRF(1-29)). The first step of this reaction involved the PEG attachment to FMOC1,12-GRF(1-29), and the second step involved the removal of FMOC moieties. This PEGylation process was optimized at the following conditions: 0.2-0.3% (v/v) triethylamine concentration, 5.0-6.0-fold molar amount of PEG, reaction temperature of 25-45 degrees C, and reaction time of 30 min. Under these conditions, the maximum yield of Lys21-PEG-GRF(1-29) produced was ca. approximately 95%, 6.3-fold higher than that by nonspecific PEGylation at pH 8.5. Significantly, this site-specific Lys21-PEG-GRF(1-29) was found to have greatly increased resistance to rat plasma, liver, and kidney homogenates, with 7.0-, 25.4-, and 16.4-fold longer half-lives vs GRF(1-29), respectively. Furthermore, 125I-Lys21-PEG-GRF(1-29) displayed significantly reduced liver and kidney distributions and extended blood presence vs 125I-GRF(1-29) in rats. Due to these benefits, Lys21-PEG-GRF(1-29) displayed an enhanced initial growth hormone release in vivo despite having 15% remaining activity in vitro. This devised PEGylation method using an FMOC-protection/deprotection strategy would provide great usefulness for PEGylating bioactive peptides in terms of improved biological potency, elevated production yield, and a uniform composition.
Study Information
pubmed
2007
2007-01-23T00:00:00.000Z
10.1021/bc060173z